Two Roads Forming
The bottom line: The system that decides which healing drugs become legal is moving slowly and carefully, while states are racing ahead on their own. If you or someone you love is waiting for a legal way to use these treatments, the safest national approval is still likely years away — but real access may reach you sooner through your own state.
Today the signals point to one steady picture. The main government drug agency — the FDA, which decides whether new medicines are safe enough to sell — is widely expected to ask for more testing before approving MDMA as a treatment for PTSD, the deep trauma that lingers after terrible experiences. The sticking point is a real one: in these studies, most people could tell whether they got the actual drug or a fake pill, because the drug's effects are so strong. That makes the results harder to trust completely. So the most likely outcome is not a "no," but a "not yet" — full approval slipping past 2027. At the same time, the country's drug-policing agency, the DEA, is expected to keep these substances in its most restricted legal category until the FDA acts. Meanwhile, states like Oregon and Colorado keep quietly building their own legal programs.
Beneath the news, two roads are forming side by side. One road is slow, federal, and cautious — it wants more proof before it opens. The other road is local and impatient — states building real clinics and trained guides while the national door stays shut. This creates a strange split: a treatment can be legal in one state and a serious crime in the next. That tension sounds messy, and it is. But there is a hopeful reading. The slow road is making the science stronger, which means that when approval finally comes, it will be solid and hard to attack. The fast road is keeping suffering people from waiting forever. Together, they may move the whole field forward faster than either could alone. The lab is also producing a quieter promise: new versions of these medicines being designed to heal without the intense trip, which could one day calm the safety worries entirely.
For the people inside this story, the waiting is the hardest part. A veteran who has tried every approved treatment and still wakes up in the grip of old nightmares does not experience "more testing" as caution — he experiences it as another year lost. A family watching someone they love run out of options feels every delay in their bones. But the most honest hope here is not a fantasy of instant approval. It is this: that within reach, in more and more states, a real and legal door is opening — staffed by trained people, done safely, done in the light. And that the careful national path, slow as it feels, is building toward an approval strong enough to last, so that relief, when it arrives, will not be snatched back. Both the patience and the urgency are serving the same person: the one who is still hurting tonight.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
The medicine is older than the fear. The healing is older than the wound.
78%
MDMA and psilocybin stay federally illegal through 2027
The DEA (the US agency that controls which drugs are legal) won't change the status of MDMA or psilocybin until the FDA (the US drug regulator) officially approves one of them as a medicine — and that approval hasn't happened yet. Until it does, both substances remain in the strictest legal category, meaning possession and use are federal crimes. This affects millions of people who might benefit from these treatments but can't access them legally.
→ MDMA and psilocybin will almost certainly remain federally illegal through 2027 because the legal trigger for changing their status — FDA approval — hasn't happened.
Resolves: 2027-12-31 · USA
REGULATION
the precise call ▾
DEA maintains Schedule I status for non-FDA-approved psychedelics (MDMA, psilocybin) through end of 2027. Federal rescheduling is statutorily tied to FDA approval, which has not occurred. Absent an approved product, DEA has no procedural trigger to reschedule, and enforcement posture is expected to hold. Consensus across DEA, legislator, and FDA reviewer agents; sole dissent from MAPS researcher reflect
72%
FDA will demand another full MDMA trial before approving it
In 2024, the FDA rejected the first application to approve MDMA-assisted therapy for PTSD (post-traumatic stress disorder), raising concerns about how the studies were run and whether participants could tell if they got the drug or a fake pill — which can skew results. The FDA is now expected to require a brand-new, large-scale clinical trial before it will reconsider approval. This means patients hoping for a legal MDMA therapy option are likely years away from getting one.
→ The FDA will almost certainly demand a new large clinical trial before approving MDMA therapy, pushing any legal treatment option years further into the future.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
FDA will require at least one additional confirmatory MDMA-PTSD trial before granting any approval. Functional unblinding and safety-monitoring concerns from the 2024 CRL remain unresolved. The agency's precedent of demanding adequate, well-controlled confirmatory data makes approval without a new trial improbable. Resolves cleanly: either FDA issues a requirement/CRL citing confirmatory data or a
70%
No reliable biological test for predicting psychedelic therapy success by 2027
Scientists are studying brain scans and biological markers trying to figure out in advance which patients will respond best to psychedelic therapy — the same way a blood test can predict how someone will respond to certain cancer drugs. Despite lots of promising research, nobody will have a test that's actually validated and ready for real clinical use by the end of 2027. This matters because without such a test, doctors can't reliably match patients to treatments.
→ Despite exciting brain science, no reliable biological test for predicting who will benefit from psychedelic therapy will exist by 2027.
Resolves: 2027-12-31 · Global
RESEARCH
the precise call ▾
No validated, FDA-recognized predictive neuroimaging or molecular biomarker for psychedelic therapy response is established by end of 2027. Mechanistic publications on plasticity and connectivity continue to grow, but translating these into a prospectively validated, clinically deployable biomarker requires large confirmatory datasets that are not yet underway. Reframed from a vague 'outpace' claim into a binary, checkable absence-of-va
65%
At least one more US state will open a legal psychedelic therapy program by mid-2027
Oregon and Colorado have already created legal, regulated programs where trained facilitators can guide people through psilocybin (the active ingredient in magic mushrooms) sessions. Several other states are moving similar bills through their legislatures, and at least one is expected to pass and begin operating by mid-2027. This gradually expands where Americans can legally access this kind of therapy without traveling abroad.
→ At least one more US state is likely to open a legal psychedelic therapy program by mid-2027, slowly expanding access beyond Oregon and Colorado.
Resolves: 2027-06-30 · USA
LEGISLATION
the precise call ▾
At least one additional US state enacts or operationalizes a psychedelic access/therapy program by mid-2027. Oregon and Colorado have established regulated psilocybin frameworks; legislative momentum in states like New Mexico and others suggests at least one more state will pass enabling legislation or open a service-provider program, outpacing the stalled federal track. Falsifiable via state legislative r